Targeting influenza virus neuraminidase - A new strategy for antiviral therapy

Drug Discovery Today

Volumn 3, Issue 10, 1998, Pages 448-456

  Oxford, John S ^a   Lambkin, Robert ^a  

^a Retroscreen Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ETHYL 4 ACETAMIDO 5 AZIDO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLATE PHOSPHATE; OSELTAMIVIR; PRODRUG; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMONIA; REVIEW;

EID: 0031786423     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(98)01241-0     Document Type: Review

References (55)

1. Monto A.S. Am. J. Med. 82:1987;20-25.
2. Noble, G. (1982) in Basic and Applied Influenza Research (Beare, A. and Boca Raton, F., eds), pp. 11-50, CRC Press.
3. Claas E.C.et al. Lancet. 351:1998;472-477.
4. Zimmerman R.K., Ruben F.L., Ahwesh E.R. J. Fam. Pract. 45:1997;107-122.
5. Hayden F.G., Hay A.J. Curr. Top. Microbiol. Immunol. 176:1992;119-130.
6. Palese P.et al. Virology. 61:1974;397-410.
7. Palese P., Complans R.W. J. Gen. Virol. 33:1976;159-163.
8. Liu C.et al. J. Virol. 69:1995;1099-1106.
9. Klenk H.D., Rott R. Adv. Virus Res. 34:1988;247-280.
10. Colman P.M.et al. Nature. 303:1983;41-44.
11. Colman, P.M. (1989) in The Influenza Viruses (Krug, R., ed.), pp. 175-218, Plenum Press.
12. Colman P.M., Hoyne P.A., Lawrence M.C. J. Virol. 67:1993;2972-2980.
13. Colman P.M. Protein Sci. 3:1994;1687-1696.
14. Wade R.C. Structure. 5:1997;1139-1145.
15. Luo M., Air G.M., Brouillette W.J. J. Infect. Dis. 176(S1):1997;S62-S65.
16. Meindl P., Tuppy H. Hoppe-Seyler's Z. Physiol. Chem. 350:1969;1088-1092.
17. von Itzstein M.et al. Nature. 363:1993;418-423.
18. Woods J.M.et al. Antimicrob. Agents Chemother. 37:1993;1473-1479.
19. Hayden F.G., Rollins B.S., Madren L.K. Antiviral Res. 25:1994;123-131.
20. Thomas G.P.et al. Antiviral Res. 24:1994;351-356.
21. Kim C.U.et al. J. Am. Chem. Soc. 119:1997;681-690.
22. Mendel D.B.et al. Antimicrob. Agents Chemother. 42:1998;640-646.
23. F. Hoffmann-La Roche (1997) Data on file. Investigational Drug Brochure.
24. Hayden, F.G. and Rollins, B.S. (1997) Antiviral Res. 34, A86 (Abstr.).
25. Hayden F.G.et al. JAMA. 275:1996;295-299.
26. Hayden F.G.et al. New Engl. J. Med. 337:1997;874-880.
27. Aoki, F. et al. (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October, Toronto, Canada, A.S.M., Washington, DC, USA, p. 384 N-15 (Abstr.).
28. Newman, S.P. et al. (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October, Toronto, Canada, A.S.M., Washington, DC, USA, p. 237 H-134 (Abstr.).
29. Li W.et al. Antimicrob. Agents Chemother. 42:1998;647-653.
30. Cundy, K.C. et al. (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October, Toronto, Canada, A.S.M., Washington, DC, USA, p. 25 A-122 (Abstr.).
31. Eisenberg E.J., Bidgood A., Cundy K.C. Antimicrob. Agents Chemother. 41:1997;1949-1952.
32. Raut S.et al. J. Med. Microbiol. 8:1975;127-136.
33. Wyde P.R.et al. Infect. Immun. 15:1977;221-229.
34. Sidwell, R.W. et al. Antiviral Res. (in press).
35. Oxford, J.S. et al. (1998) European Society for Clinical Virology - Progress in Virology VI, 30 August-2 September, Hamburg, Germany.
36. Wiltshire, H.R. et al. (1998) European Society for Clinical Virology - Progress in Virology VI, 30 August-2 September, Hamburg, Germany.
37. Wood, N.D. et al. (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October, Toronto, Canada, A.S.M., Washington, DC, USA, p. 25 A-123 (Abstr.).
38. Hayden, F.G. et al. (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September-1 October, Toronto, Canada, A.S.M., Washington, DC, USA, p. 7 LB-26 (Abstr.).
39. Treanor, J.J. et al. (1998) 11th International Conference of Antiviral Research, 5-11 April, San Diego, CA, USA (Abstr.).
40. Centers for Disease Control and Prevention (1996) MMWR 45 (RR-5), 1-24.
41. Advisory Committee on Immunization Practices (1997) MMWR 46 (RR-9), 1-25.
42. Murphy, B.R. and Webster, R.G. (1996) in Fields' Virology (3rd edn) (Fields, B., et al., eds), pp. 1397-1445, Philadelphia, Lippincott-Raven.
43. Nichol K.L. Arch. Intern. Med. 156:1996;1546-1550.
44. Nichol K.L.et al. New Engl. J. Med. 33:1995;889-893.
45. Glezen W.P. Epidemiol. Rev. 18:1996;64-76.
46. Piedra P. Semin. Respir. Infect. 10:1995;216-223.
47. Wright P.F.et al. Pediatrics. 67:1981;694-700.
48. Nicholson K.G. Semin. Respir. Infect. 7:1992;26-37.
49. Beyer W.E.P., Palache A.M., Osterhaus A.D.M.E. Clin. Drug Invest. 15:1998;1-12.
50. Palache A.M. Drugs. 54:1997;841-856.
51. Hay A.J. Semin. Virol. 3:1992;21-30.
52. Hayden F.G.et al. Antimicrob. Agents Chemother. 19:1981;226-233.
53. Dolin R.et al. New Engl. J. Med. 307:1982;580-584.
54. Ward, M.R. (1997) Nurse Pract. 22, 45-46,49-50,52-53.
55. Stuart-Harris, C.H., Schild, G.C. and Oxford, J.S. (1985) in Influenza: The Viruses and the Disease (2nd edn), Edward Arnold.